Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.